nm23、p53基因突变与膀胱癌生物学特性的关系

MUTATION AND SIGNIFICANCE OF TUMOR METASTASIS SUPPRESSOR GENE nm23 AND SUPPRESSOR GENE p53 IN BLADDER CANCER

目的 :检测膀胱癌组织中 nm2 3和 p53基因外显子突变情况 ,寻找有助于准确预测局部肿瘤进展、分型、预后情况的临床参照指标。 方法 :应用 PCR- SSCP检测 2 8例膀胱癌术后存档蜡块组织中nm2 3及 p53基因外显子突变情况 ,并与膀胱癌的病理及临床指标进行相关性研究。结果 :nm2 3及 p53基因突变率分别为 1 4.3%及 1 7.99%。nm2 3及 p53基因突变均发生在低分化组及有淋巴结转移病例。nm2 3和/或 p53基因突变与 UICC临床分期和淋巴结转移均呈正相关 ( P<0 .0 1 )。结论 :nm2 3和 /或 p53基因突变与膀胱癌恶性程度进展有关 ,与肿瘤淋巴结转移有密切关系。 nm2 3及 p53基因突变在判断膀胱癌细胞增殖、分化程度、恶性进度及预后转归方面有一定价值 ,可作为判断膀胱癌预后的参考指标 ,指导高危患者的进一步治疗。

Objective: Our study aimed to investigate whether nm23 and p53 gene mutation in the primary bladder tumor correlated with tumor grade stage recurrence metastasis and patient survival time. Methods:PCR SSCP is used to test the exon mutation in nm23 and p53 of the samples. 28 cases paraffin embeded samples were admitted. Results: The gene mutation rate of nm23 and p53 were 14.3% and 17.9%. All mutations happened in the low grade tumor and lymph node metastasis. In this study, nm23 and p53 gene mutation was correlated with histological grade and clinical stage and closely correlated with lymph node metastasis. Conclusion: We found that nm23 and p53 play an important role in the development and progression of bladder cancer. nm23 and p53 appear to be associated with the proliferation and progression of bladder cancer. Both of them can be used as prognostic factors in bladder cancer.